Please assess the completion status of the following clinical trial:

Trial Title: A Trial of Immunological Outcomes of Sublingual Immunotherapy for House Dust Mite (D. Pteronyssinus) Allergy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* allergic rhinitis and/or~* mild stable asthma~* house dust mite allergic~* positive HDM-specific IgE as determined by skin prick test (wheal diameter \>6 mm to D. pteronyssinus) or CAP-Pharmacia score \> 2~Exclusion Criteria:~* Immunodeficiency diseases~* Severe or uncontrolled asthma~* Previous immunotherapy with House dust mite (HDM) extract within the last five years or ongoing immunotherapy with HDM or other allergens~* Continuous oral corticosteroids~* Subjects on treatment with beta-blockers~* Pregnant women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: PLACEBO_COMPARATOR): Matching placebo- control arm (first year)
- 2 (Type: ACTIVE_COMPARATOR): Drug Staloral (active group)

Based on this trial design, predict the completion outcome and termination type (if applicable).